Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21993936 | 1.00 | CHRNA7 (0.37) | CHRNA7PIK3CD | |
| SCHEMBL18721992 | 0.80 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL15871255 | 0.74 | CHRNA7 (0.42) | CHRNA7PIK3CD | |
| SCHEMBL21993858 | 0.72 | CHRNA7 (0.41) | CHRNA7PIK3CD | |
| SCHEMBL16302657 | 0.72 | CHRNA7 (0.41) | CHRNA7PIK3CD | |
| SCHEMBL24245135 | 0.65 | CHRNA7 (0.39) | CHRNA7PIK3CD | |
| SCHEMBL10304537 | 0.65 | SIRT2 (0.32) | — | |
| SCHEMBL6551919 | 0.65 | — | — | |
| SCHEMBL20850721 | 0.64 | CHRNA7 (0.35) | CHRNA7PIK3CD | |
| SCHEMBL20354934 | 0.64 | CHRNA7 (0.38) | CHRNA7PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | CHRNA7 4867/4885PIK3CD 1955/4885 |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | CHRNA7 4867/4885PIK3CD 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.